Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit
FASCO 2027: Recognizing Dedication to Oncology
ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results
A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer
Jeff Dunn on Cancer Equity: The Powerful Message Behind “Poverty Is a Carcinogen”
Arun Azad: New TALAPRO-2 Data Highlight the Prognostic Value of ctDNA and CTCs in Prostate Cancer
Top Gastroesophageal Cancer Updates From ESMO 2026
Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
